Solesta approved by FDA as fecal incontinence treatment
SILVER SPRING, Md. — The Food and Drug Administration has approved an injectable gel for fecal incontinence, the agency said.
The FDA announced the approval of Oceana Therapeutics’ Solesta for patients who have involuntarily lost bowel control and for whom such therapies as diet change, fiber therapy and antimotility medications have failed.
Fecal incontinence affects more than 5.5 million Americans, according to the National Institutes of Health.
NACDS Foundation names beneficiaries of Community PREP grant program
ALEXANDRIA, Va. — Purdue University, the University of Missouri and the University of North Carolina were the beneficiaries of a $1.5 million grant program designed to expand community pharmacy residency programs for recent school graduates.
The National Association of Chain Drug Stores Foundation announced on Thursday that the academic institutions were the first three beneficiaries of the Community Pharmacy Residency Expansion Project (Community PREP) grant program.
For this first round of awards, the recipients were:
Purdue University, with practice sites at Kroger;
University of Missouri – Kansas City, with practice sites at Red Cross Pharmacy; and
University of North Carolina, with practices sites at Kerr Drug.
Over the next three years, each of the grant recipients will receive $50,000 from the NACDS Foundation to support the development of a residency position for graduates of accredited schools and colleges of pharmacy.
Established in 2010, Community PREP seeks to create 30 new, fully accredited post-graduate year-one community pharmacy residency opportunities through grants to nonprofit pharmacy schools and colleges. The grants are designed to foster the creation or expansion of a patient-focused residency program, where a faculty member or preceptor will oversee the selected pharmacy resident’s learning experience at a pharmacy practice site. Grant recipients are determined based on the recommendations of an independent review committee comprised of representatives from the American Association of College of Pharmacy, the American Pharmacists Association and the NACDS Foundation.
“The Community PREP grant program was developed to provide expanded opportunities for pharmacy school graduates to pursue community pharmacy residencies and hone their skills in providing patient care services,” NACDS Foundation president Edith Rosato said. “I commend these three prestigious recipients for their dedication to patient care and their laudable commitment to mentoring the next generation of pharmacy graduates.”
Community PREP grant applications are accepted on a continuing basis, with a deadline of July 1. Twelve additional grants will be awarded in 2011, and another 15 will be awarded in 2012.
Teva to market generic Combivir tablets
JERUSALEM — Teva Pharmaceutical Industries is set to market a generic version of an HIV treatment, the drug maker announced Thursday.
Teva said it will launch generic Combivir tablets (lamivudine and zidovudine) and is eligible for a 180-day period of marketing exclusivity, according to the Food and Drug Administration. The drug maker is expected to ship the drug in fourth quarter 2011, per terms of a settlement agreement between Teva, Glaxo Group and ViiV Healthcare.
Combivir tablets had annual sales of approximately $315 million in the United States, according to IMS sales data.